Article
CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
Alimentary pharmacology & therapeutics - 15 Jun 2003
Egan L J, Myhre G M, Mays D C, Dierkhising R A, Kammer P P, Murray J A
Abstract excerpt
BACKGROUND: The rate of metabolic inactivation of proton-pump inhibitors is determined by polymorphisms of CYP2C19. It is not known if CYP2C19 variant alleles affect responses to proton-pump inhibitor therapy in gastro-oesophageal reflux disease (GERD). AIM: To determine if the CYP2C19 genotype is associated with clinical effectiveness of proton-pump inhibitors during GERD therapy. METHODS: GERD patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.